In biologics and cold-chain products, temperature excursions during shipping or storage can destroy a batch worth crores.

That’s where a Freeze-Thaw Study comes in. It proves whether your drug product can survive accidental freezing and thawing without losing quality, safety, or efficacy.

1. Why Do We Need a Freeze-Thaw Study?

Not all products are stored at 2-8°C in perfect conditions. During:

• Shipping: Dry ice, winter transport, airport tarmac
• Warehouse: Power failure in cold room
• Hospital: Kept in -20°C freezer by mistake

Regulators like USFDA, EMA, WHO, ICH Q1A, Q5C expect data to show what happens if the product freezes and thaws.

Key Purpose: To set handling instructions, shipping validation limits, and to support “Do Not Freeze” or “Can be frozen” label claims.

2. Regulatory References

3. When is a Freeze-Thaw Study Required?

1. Biologics & Proteins: mAbs, Vaccines, Insulin, Biosimilars – Most sensitive to freezing
2. Drug Products stored at 2-8°C: To justify “Do Not Freeze” warning
3. Bulk Drug Substance: If stored frozen at -20°C or -80°C and thawed for use
4. Shipping Validation: To support worst-case winter shipping

4. How to Design a Freeze-Thaw Study: Step-by-Step

Step 1: Define Cycles

1 cycle = Freeze for X hours + Thaw for X hours

Common Design: 3 to 5 cycles. Example: Freeze at -20°C for 24h, Thaw at 2-8°C for 24h

Rationale: 3 cycles cover most real-world excursions. 5 cycles for high-risk biologics.

Step 2: Select Containers

Test in final container closure system and also in bulk containers if applicable. Use minimum fill volume – worst case.

Step 3: Test Parameters / CQAs

Test before and after each cycle. Focus on quality attributes affected by freezing:

• Physical: Appearance, Particulate matter, pH, Osmolality
• Chemical: Assay, Related substances, Degradation products
• Biological: Potency, Binding activity
• Protein Specific: Aggregation by SEC-HPLC, Particles by LO, Charge variants by IEC

Step 4: Acceptance Criteria

Product should meet release specifications after all cycles. No new peaks, no increase in aggregates >10%, no visible particles.

5. Common Acceptance Criteria Example

6. Impact on Labeling and Handling

Case A: Product Passes

Label can say: “Protect from light. Store at 2-8°C. Do not freeze.” OR “Stable to 3 freeze-thaw cycles”

Case B: Product Fails

Label must have: “DO NOT FREEZE”. Add freeze indicators in shipping shippers. Train warehouse staff.

7. Common Mistakes During Freeze-Thaw Studies

• ❌ Using only 1 cycle. Regulators expect multiple cycles
• ❌ Testing in glass vial but shipping in plastic bag – container mismatch
• ❌ Not testing potency and aggregation – only doing assay
• ❌ No rationale for number of cycles chosen
• ❌ Slow freezing in -20°C freezer vs flash freezing – affects ice crystal formation

8. Freeze-Thaw vs Thermal Cycling vs Cold Chain Validation

Freeze-Thaw Study: Lab study on product to check stability
Thermal Cycling: Equipment qualification for stability chambers
Cold Chain/Shipping Validation: Real shipping lane study with temp loggers

All 3 are linked but different.

Conclusion

A Freeze-Thaw study is not just a stability checkbox. It directly protects patients and prevents batch loss during distribution.

Rule of thumb in global pharma: “If it can freeze in real life, you must prove it in the lab first.”

For QA and Stability teams, having robust freeze-thaw data is the difference between “Approved for global shipping” and “Restricted to local market only”.